Noxopharm Ltd (ASX:NOX) CEO and managing director Dr Graham Kelly speaks to Proactive's Andrew Scott after reporting positive interim data from its NOXCOVID trial. The interim data points to Veyonda in a cohort of 18 patients with moderately severe COVID19 disease, providing protection against progression of severe inflammation associated with a worsening of the disease.
Noxopharm CEO encouraged by positive interim data from NOXCOVID trial
Quick facts: Noxopharm Ltd
Price: 0.565 AUD
Market Cap: $162.88 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...FOR OUR FULL DISCLAIMER CLICK HERE